Experienced in Myelofibrosis

Dr. Thomas R. Chauncey

Hematology Oncology | Oncology
1660 S Columbian Way, Marrow Transplant Unit (111), 
Seattle, WA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Myelofibrosis
1660 S Columbian Way, Marrow Transplant Unit (111), 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Thomas Chauncey is a Hematologist Oncology specialist and an Oncologist in Seattle, Washington. Dr. Chauncey is rated as an Experienced provider by MediFind in the treatment of Myelofibrosis. His top areas of expertise are Mantle Cell Lymphoma (MCL), Leukemia, Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), and Bone Marrow Transplant. Dr. Chauncey is currently accepting new patients.

His clinical research consists of co-authoring 48 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 2 clinical trials in the study of Myelofibrosis.

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in WA
Languages Spoken
English
Hindi
Korean
Spanish
Telugu
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Premera
  • EPO
  • PPO

Locations

1660 S Columbian Way, Marrow Transplant Unit (111), Seattle, WA 98108

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: April 17, 2025
Intervention Type: Drug
Transplantation of Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation or Cyclophosphamide/Fludarabine/Thiotepa/Total Body Irradiation Myeloablative Preparative Regimen
Transplantation of Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation or Cyclophosphamide/Fludarabine/Thiotepa/Total Body Irradiation Myeloablative Preparative Regimen
Enrollment Status: Completed
Publish Date: March 07, 2025
Intervention Type: Drug, Other, Procedure, Radiation
Study Drugs: Cyclophosphamide, Cyclosporine, Fludarabine, Mycophenolate Mofetil, Thiotepa
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Enrollment Status: Terminated
Publish Date: January 23, 2023
Intervention Type: Drug, Biological, Radiation, Procedure
Study Drugs: Cyclophosphamide, Filgrastim, Fludarabine, Mycophenolate Mofetil, Tacrolimus
Study Phase: Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
A Phase II Study of Optimally Dosed Clofarabine in Combination With Low-Dose TBI to Decrease Relapse Rates After Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients With AML
A Phase II Study of Optimally Dosed Clofarabine in Combination With Low-Dose TBI to Decrease Relapse Rates After Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients With AML
Enrollment Status: Completed
Publish Date: April 16, 2020
Intervention Type: Drug, Procedure, Radiation, Other
Study Phase: Phase 2
Low-Dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection After Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders - A Multi-Center Trial
Low-Dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection After Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders - A Multi-Center Trial
Enrollment Status: Completed
Publish Date: January 31, 2020
Intervention Type: Radiation, Procedure, Drug, Other
Study Phase: Phase 2
A Phase II Study to Assess Immunosuppression With Sirolimus Combined With Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD After Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation- A Multi-Center Trial
A Phase II Study to Assess Immunosuppression With Sirolimus Combined With Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD After Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation- A Multi-Center Trial
Enrollment Status: Completed
Publish Date: December 09, 2019
Intervention Type: Drug, Radiation, Other, Procedure
Study Phase: Phase 2
View 7 Less Clinical Trials

48 Total Publications

Proteogenomic characterization of highly enriched viable leukemic blasts in acute myeloid leukemia: A SWOG report.
Proteogenomic characterization of highly enriched viable leukemic blasts in acute myeloid leukemia: A SWOG report.
Journal: EJHaem
Published: September 09, 2024
Similar Doctors
Elite in Myelofibrosis
Dr. Rachel B. Salit
Hematology Oncology | Hematology | Oncology
Elite in Myelofibrosis
Dr. Rachel B. Salit
Hematology Oncology | Hematology | Oncology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (4.5 miles away)
206-288-1000
Languages Spoken:
English, German, Mandarin, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Rachel Salit is a Hematologist Oncology specialist and a Hematologist in Seattle, Washington. Dr. Salit is rated as a Distinguished provider by MediFind in the treatment of Myelofibrosis. Her top areas of expertise are Myelofibrosis, Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), and Bone Marrow Transplant. Dr. Salit is currently accepting new patients.

Distinguished in Myelofibrosis
Dr. Anna B. Halpern
Hematology Oncology | Hematology | Oncology
Distinguished in Myelofibrosis
Dr. Anna B. Halpern
Hematology Oncology | Hematology | Oncology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (4.5 miles away)
206-288-1000
Languages Spoken:
English, Hindi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Anna Halpern is a Hematologist Oncology specialist and a Hematologist in Seattle, Washington. Dr. Halpern is rated as a Distinguished provider by MediFind in the treatment of Myelofibrosis. Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Chronic Myelomonocytic Leukemia (CMML), and Bone Marrow Aspiration. Dr. Halpern is currently accepting new patients.

Advanced in Myelofibrosis
Dr. Jack W. Singer
Hematology Oncology
Advanced in Myelofibrosis
Dr. Jack W. Singer
Hematology Oncology
Harborview Medical Center, 325 9th Ave, 
Seattle, WA 
 (2.9 miles away)
206-731-3000
Languages Spoken:
English

Jack Singer is a Hematologist Oncology provider in Seattle, Washington. Dr. Singer is rated as an Advanced provider by MediFind in the treatment of Myelofibrosis. His top areas of expertise are Myelofibrosis, Non-Hodgkin Lymphoma, Splenomegaly, and Thrombocytopenia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chauncey's expertise for a condition
ConditionClose
      View All 18 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile